The complaint alleges that Mindray broke a more than 10-year-old deal to incorporate Masimo’s pulse oximetry technology into its Beneview device and violated 9 Masimo patents in the process, according to court documents.
“Over the last several years, Masimo experienced a significant drop in Mindray Shenzhen’s purchasing of Masimo SET boards. Over this same period, Masimo’s share of the market for pulse oximetry monitors has increased significantly,” according to the lawsuit. “In addition, Mindray Shenzhen’s breaches, including its continuing efforts to market and promote its own SpO2 products to the detriment of Masimo have caused and will continue to cause irreparable harm to Masimo, unless enjoined by the court.”
Mindray said it "intends to vigorously defend the actions," according to a press release.